Home > News > GST and Boehringer Ingelheim awarded Best Mid-Cap Corporate Deal by the Belgian M&A awards
Print pageprint Stay Informedprint

NEWS

GST and Boehringer Ingelheim awarded Best Mid-Cap Corporate Deal by the Belgian M&A awards

calendar_new
19/03/2021
Related Lawyer(s)

Congratulations to Global Stem Cell Technology (GST) and Boehringer Ingelheim for being awarded Best Mid-Cap Corporate Deal by the Belgian M&A awards. A Liedekerke team consisting of partner Wim Dedecker and associates Ellen Vermeire and Max Le Blanc assisted Boehringer Ingelheim on this transaction.

Wim Dedecker adds: “It has been a real privilege working on a deal of such strategic importance, which demonstrates the unique quality of our Belgian biotech ecosystem. Congratulations to all involved – this is very well deserved

Read more about the deal here.